Crucell Terug naar discussie overzicht

Brussel akkoord met overname Crucell

1. voda 28 januari 2011 18:12

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 92325

     Gegeven: 22693

   •    Aantal posts: 382.335

   Brussel akkoord met overname Crucell
   28 januari 2011, 18:08 | ANP
   BRUSSEL (AFN) - De Europese Commissie heeft vrijdag ingestemd met de overname van het Nederlandse Crucell door het Amerikaanse farmacieconcern Johnson & Johnson.
   
   Crucell is actief in de ontwikkeling, productie en verkoop van biologische geneesmiddelen voor de preventie en de behandeling van besmettelijke ziektes. Volgens de Europese Commissie is de overname niet in strijd met EU-regels over mededinging.
   
   Aandeelhouders van Crucell hadden vorige maand tijdens een buitengewone vergadering moeite met de overname, omdat het bod van 24,75 euro per aandeel te laag zou zijn.
   
   
2. bilbo3 28 januari 2011 18:28

   auteur info

   • bilbo3

     Lid sinds: 01 sep 2005

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 578

     Gegeven: 209

   •    Aantal posts: 715

   Brussel is accoord, maar wij nog lang niet!!!!
3. voda 28 januari 2011 19:52

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 92325

     Gegeven: 22693

   •    Aantal posts: 382.335

   Haha, DJ loopt een beetje achter. :-)
   Crucell en Johnson & Johnson hebben toestemminig gekregen EU voor overname
   
   
   (MORE TO FOLLOW) Dow Jones Newswires
   
   
4. voda 28 januari 2011 20:07

   auteur info

   • voda

     Lid sinds: 02 dec 2005

     Laatste bezoek: 31 jan 2025

   • Aanbevelingen

     Ontvangen: 92325

     Gegeven: 22693

   •    Aantal posts: 382.335

   Crucell en Johnson & Johnson krijgen toestemming EU voor overname
   
   
   AMSTERDAM (Dow Jones)--Crucell nv (CRXL.AE) en Johnson & Johnson (JNJ) hebben toestemming gekregen van de Europese Commissie voor de overname van het Nederlandse biotechbedrijf, maakt Crucell vrijdag bekend.
   
   Johnson & Johnson biedt EUR24,75 per aandeel Crucell, en het bod wordt volledig gesteund door de Raad van Bestuur en Raad van Commissarissen van Crucell.
   
   De biedingsperiode loopt tot 16 februari 17.45 uur. Ook wordt op 8 februari nog een extra buitengewone aandeelhoudersvergadering gehouden.
   
   
   Door Levien de Feijter; Dow Jones Nieuwsdienst +31 20 57 15 201; levien.defeijter@dowjones.com
   
   
5. flosz 28 januari 2011 21:28

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Johnson & Johnson Receives Approval from European Commission
   
   NEW BRUNSWICK, N.J. and LEIDEN, Netherlands, Jan. 28, 2011 /PRNewswire/ -- Johnson & Johnson and Crucell today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell.
   Reference is made to the joint press release of Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) dated 8 December 2010 announcing the recommended cash offer by Johnson & Johnson for all of the issued and outstanding ordinary shares in the capital of Crucell N.V. (Crucell), including those represented by American depositary shares, at an offer price of euro 24.75 per share (the Offer).
   With this approval an important Offer condition has been fulfilled.
   As announced on 8 December 2010, the remaining timetable of the Offer process is as follows:
   • 8 February 2011: the Offer Extraordinary General Meeting (Offer EGM).
   • 16 February 2011, 17:45 hours Dutch time (11:45 a.m. New York time), unless extended: Acceptance Closing Time.
   
   Further information regarding the Offer is contained in the offer document and the position statement which are available free of charge on the website of Crucell at www.crucell.com.
   Additional Information
   This joint press release is issued pursuant to the provisions of Section 4 paragraph 3 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) and Section 5:25i of the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht).
   On December 8, 2010, JJC Acquisition Company B.V. (the Offeror), a wholly owned subsidiary of Johnson & Johnson, commenced the Offer to acquire all of the issued and outstanding ordinary shares (Ordinary Shares) in the capital of Crucell, including all Ordinary Shares represented by American depositary shares (each, an ADS), on the terms and subject to the conditions and restrictions contained in the Offer Document dated December 8, 2010 (the Offer Document). Shareholders who accept the Offer and tender Ordinary Shares will be paid, on the terms and subject to the conditions and restrictions contained in the Offer Document, an amount equal to euro 24.75, net to the Shareholders in cash, without interest and less any applicable withholding taxes (the Offer Price) in consideration of each Ordinary Share, subject to the Offeror declaring the Offer unconditional. Shareholders who accept the Offer and tender ADSs will be paid, on the terms and subject to the conditions and restrictions contained in the Offer Document, an amount equal to the U.S. dollar equivalent of the Offer Price, calculated by using the spot market exchange rate for the U.S. dollar against the Euro on the date on which funds are received by Computershare Trust Company, N.A. to pay for ADSs upon completion of the Offer, in consideration of each ADS, subject to the Offeror declaring the Offer unconditional. The offer and withdrawal rights will expire at 17:45 hours Dutch time (11:45 a.m. New York time), on February 16, 2011, unless extended in the manner set forth in the Offer Document. This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Crucell, nor shall there be any sale or purchase of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Offer is being made pursuant to the tender offer statement on Schedule TO (including the Offer Document, a related ADS letter of transmittal and tender and proxy form, and other relevant materials) filed by the Offeror with the U.S. Securities and Exchange Commission (SEC) on December 8, 2010.
   SHAREHOLDERS OF CRUCELL ARE URGED TO READ THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE OFFER. Copies of Johnson & Johnson’s filings with the SEC may be obtained at the SEC’s web site (www.sec.gov) or by directing a request to Johnson & Johnson at Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933, U.S.A. (Attention: Corporate Secretary’s Office). The Offer Document is available free of charge on the website of Crucell at www.crucell.com. Hard copies of the Offer Document will also be available at the offices of Crucell at Archimedesweg 4-6, 2333 CN Leiden, the Netherlands; at the offices of the Dutch Settlement Agent, ING Bank N.V., Bijlmerdreef 888 1102 MG Amsterdam, the Netherlands (Attention: Sjoukje Hollander/Remko Los), telephone: + 31 20 563 6546 / + 31 20 563 6619, email: iss.pas@ing.nl); and at the offices of the U.S. Settlement Agent, Computershare Trust Company, N.A., 250 Royall Street, Canton, MA 02021.
   About Crucell
   Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2009 alone, Crucell distributed more than 115 million vaccine doses in more than 100 countries around the world, with the vast majority of doses (97%) going to developing countries. Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine. Called Quinvaxem®, this innovative combination vaccine protects against five important childhood diseases. Over 180 million doses have been sold since its launch in 2006 in more than 50 GAVI countries. With this innovation, Crucell has become a major partner in protecting children in developing countries. Other products in Crucell's core portfolio include a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as an oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. Crucell has a broad development pipeline, with several product candidates based on its unique PER.C6® production technology. Crucell licenses its PER.C6® technology and other technologies to the biopharmaceutical industry. Important partners and licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Pfizer/Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, UK, the USA and Vietnam. Crucell employs over 1300 people. For more information, please visit www.crucell.com.
   About Johnson & Johnson
   Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day throughout the world.
   hugin.info/132631/R/1483491/418700.pdf
6. [verwijderd] 28 januari 2011 23:21

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Wat een prachtbedrijf is Crucell toch.
   
   J+J is wel groot maar is niet zo mooi.
   
   Uitermate vreemd dat men nog steeds vast houdt aan E 24.75.
   
   8 feb staan er merkwaardige voorstellen op tafel met opzijschuiven van huidige commissarissen voor mensen uit J+J stal alsof J+J echt kans maakt om Crucell over te nemen.
   
   Laat je stem niet verloren gaan als je niet kan en bel je bank om de VEB te machtigen. Die vinden dit ook niet gepast.
   Wellicht moet wel Floris Waller vervangen worden door iemand waar VEB en ook van herk wel fiducie in hebben. je kan VEB pere-mail laten weten wat je wil dat er met je stemmen gebeurt.
   Zelf heb ik een groot deel van mijn aandelen stemecht aan VEB overgedragen maar heb ook op mijn eigen naam geregistreerd zodat ik ook aanwezig kan zijn mocht dat timewise lukken.